| Literature DB >> 33660138 |
Lieke A M W Wijnhoven1,2,3, Rutger C M E Engels4,5, Patrick Onghena5,6, Roy Otten4,6,7,8,9, Daan H M Creemers10,4,6,8.
Abstract
The aim of the present study was to examine the additive effect of elements of cognitive behavioral therapy (CBT) on the video game Mindlight in decreasing anxiety of children with an autism spectrum disorder (ASD). A non-concurrent multiple baseline design with 8 children with ASD in the age of 8-12 was used. CBT did not have the hypothesized additive effect on Mindlight in decreasing anxiety of children with ASD. Instead, multiple participants already experienced a decrease in anxiety during the Mindlight sessions. Yet, several participants did experience a stabilization in anxiety at a low level during the CBT sessions. For now, it can be concluded that CBT does not have an additive effect on Mindlight.Entities:
Keywords: Anxiety symptoms; Autism spectrum disorders; Children; Cognitive-behavioral therapy; Video game
Mesh:
Year: 2021 PMID: 33660138 PMCID: PMC8732870 DOI: 10.1007/s10803-021-04927-8
Source DB: PubMed Journal: J Autism Dev Disord ISSN: 0162-3257
Fig. 1Overview of daily measurements (0–70) and the time points for the start of Mindlight (M), CBT (T) and T1–T3 in all four baselines (A = 4, B = 5, C = 6, D = 7 Mindlight sessions)
Participants’ profile of subclinical and clinical anxiety symptoms based on the scores on the SCAS-C/P at T0 and the ADIS-P at T1
| Separation anxiety | Social phobia | Specific phobia | Generalized anxiety | Panic disorder/agoraphobia | |
|---|---|---|---|---|---|
| Participant 1 | |||||
| Subclinical | X | ||||
| Clinical | X | X | |||
| Participant 2 | |||||
| Subclinical | X | X | X | ||
| Clinical | X | ||||
| Participant 3 | |||||
| Subclinical | X | ||||
| Clinical | X | X | |||
| Participant 4 | |||||
| Subclinical | |||||
| Clinical | X | X | X | ||
| Participant 5 | |||||
| Subclinical | X | X | |||
| Clinical | X | X | |||
| Participant 6 | |||||
| Subclinical | |||||
| Clinical | X | ||||
| Participant 7 | |||||
| Subclinical | X | ||||
| Clinical | X | X | X | ||
| Participant 8 | |||||
| Subclinical | X | ||||
| Clinical | X | X | |||
Fig. 2Course of daily measured anxiety level (0–10) over 70 days for participant 1
Fig. 3Course of daily measured anxiety level (0–10) over 70 days for participant 2
Fig. 4Course of daily measured anxiety level (0–10) over 70 days for participant 3
Fig. 5Course of daily measured anxiety level (0–10) over 70 days for participant 4
Fig. 6Course of daily measured anxiety level (0–10) over 70 days for participant 5
Fig. 7Course of daily measured anxiety level (0–10) over 70 days for participant 6
Fig. 8Course of daily measured anxiety level (0–10) over 70 days for participant 7
Fig. 9Course of daily measured anxiety level (0–10) over 70 days for participant 8
Differences and RCI’s for SCAS scores between T0 and T4 (screening-3 months FU), T1–T2 (pre-test–post-Mindlight), T2–3 (post-Mindlight–post-CBT) and T3–4 (post-CBT—3 months FU) for every participant
| pp1 | pp2 | pp3 | pp4 | pp5 | pp6 | pp7 | pp8 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diff | RCI | Diff | RCI | Diff | RCI | Diff | RCI | Diff | RCI | Diff | RCI | Diff | RCI | Diff | RCI | |
| T0–T4 | 12 | 2.15 | 20 | 3.58 | 0 | .00 | 4 | .72 | 2 | .36 | 5 | .90 | 7 | 1.25 | 9 | 1.61 |
| T1–T2 | 5 | .90 | 1 | .18 | 4 | .72 | 3 | .54 | − 4 | − .73 | − 2 | − .36 | 0 | .00 | 7 | 1.25 |
| T2–T3 | − 3 | − .54 | 6 | 1.08 | 8 | 1.43 | 3 | .54 | 14 | 2.54 | 1 | .18 | 4 | .72 | 3 | .54 |
| T3–T4 | 5 | .90 | 6 | 1.08 | − 6 | − 1.08 | 6 | 1.08 | − 4 | − .73 | − 4 | − .72 | − 3 | − .54 | 0 | .00 |
Diff difference
RCI > 1.96 indicates a clinically significant decrease
Differences and RCI’s for parent-rated SCAS scores between T0 and T4 (screening-3 months FU), T1–T2 (pre-test–post-Mindlight), T2–3 (post-Mindlight–post-CBT) and T3–4 (post-CBT—3 months FU) for every participant
| pp1 | pp2 | pp3 | pp4 | pp5 | pp6 | pp7 | pp8 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diff | RCI | Diff | RCI | Diff | RCI | Diff | RCI | Diff | RCI | Diff | RCI | Diff | RCI | Diff | RCI | |
| T0–T4 | 14 | 2.57 | 8 | 2.05 | − 3 | − .55 | 8 | 1.47 | 3 | .71 | 14 | 2.57 | 19 | 3.49 | 7 | 1.29 |
| T1–T2 | 4 | .74 | − 5 | − 1.18 | 7 | 1.29 | 3 | .55 | − 4 | − .95 | − 6 | − 1.10 | 9 | 1.65 | − 1 | − .18 |
| T2–T3 | 6 | 1.10 | 9 | 2.13 | 2 | .37 | 1 | .18 | − 2 | − .47 | 9 | 1.65 | 0 | .00 | 1 | .18 |
| T3–T4 | − 2 | − .37 | − 15 | − 3.55 | − 7 | − 1.29 | 6 | 1.10 | 5 | 1.18 | − 1 | − .18 | 0 | .00 | 7 | 1.29 |
Diff difference
RCI > 1.96 indicates a clinically significant decrease